These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 34221962)

  • 21. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.
    Xing W; Dresser K; Zhang R; Evens AM; Yu H; Woda BA; Chen BJ
    Oncotarget; 2016 Sep; 7(37):59976-59986. PubMed ID: 27527850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
    Ishikawa E; Kato S; Shimada K; Tanaka T; Suzuki Y; Satou A; Kohno K; Sakakibara A; Yamamura T; Nakamura M; Miyahara R; Goto H; Nakamura S; Hirooka Y
    Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-1 expression on tumour-infiltrating cells is a prognostic factor for relapsed or refractory diffuse large B-cell lymphoma.
    Wada F; Kamijo K; Shimomura Y; Yamashita D; Hara S; Ishikawa T
    Immunology; 2024 Feb; 171(2):224-234. PubMed ID: 37904615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-neoplastic cells as prognostic biomarkers in diffuse large B-cell lymphoma: A system review and meta-analysis.
    Zhao M; Wang L; Wang X; He J; Yu K; Li D
    Tumori; 2024 Aug; 110(4):227-240. PubMed ID: 38183180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of selenium on regulatory T cell frequency and immune checkpoint receptor expression in patients with diffuse large B cell lymphoma (DLBCL).
    Dehghani M; Shokrgozar N; Ramzi M; Kalani M; Golmoghaddam H; Arandi N
    Cancer Immunol Immunother; 2021 Oct; 70(10):2961-2969. PubMed ID: 33721055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic Subtypes of Systemic Anaplastic Large Cell Lymphoma Show Distinct Differences in PD-L1 Expression and Regulatory and Cytotoxic T Cells in the Tumor Microenvironment.
    Ferreira CR; Manohar V; Zhao S; Bangs CD; Cherry A; Azevedo RS; Lage LAPC; Pereira J; Zerbini MCN; Gratzinger D; Natkunam Y
    Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):10-16. PubMed ID: 31809310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
    Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
    Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells.
    Ma J; Yan S; Zhao Y; Yan H; Zhang Q; Li X
    Front Immunol; 2023; 14():1265255. PubMed ID: 37841254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune Checkpoint Molecules in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.
    Monabati A; Nematollahi P; Dehghanian A; Safaei A; Sadeghipour A; Movahedinia S; Mokhtari M
    Basic Clin Neurosci; 2020; 11(4):491-498. PubMed ID: 33613887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma.
    You H; Xu-Monette ZY; Wei L; Nunns H; Nagy ML; Bhagat G; Fang X; Zhu F; Visco C; Tzankov A; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Hagemeister FB; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Van Krieken JH; Piris MA; Winter JN; Li Y; Au Q; Xu B; Albitar M; Young KH
    Oncoimmunology; 2021; 10(1):1928365. PubMed ID: 34350060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variant.
    El Hussein S; Medeiros LJ; Gruschkus SK; Wei P; Schlette E; Fang H; Jelloul FZ; Wang W; Fiskus W; Kanagal-Shamanna R; Loghavi S; Yang H; Li S; Xu J; Tang Z; Thakral B; Jain N; Wierda WG; Patel K; Bhalla KN; Khoury JD
    Virchows Arch; 2023 Jun; 482(6):1011-1019. PubMed ID: 36864257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A unique expression pattern of LAG3 distinct from that of other immune checkpoints in diffuse large B-cell lymphoma.
    Lee H; Yoon SE; Kim SJ; Kim WS; Cho J
    Cancer Med; 2023 Aug; 12(15):16359-16369. PubMed ID: 37326144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic implications of tumor-infiltrating macrophages, M2 macrophages, regulatory T-cells, and indoleamine 2,3-dioxygenase-positive cells in primary diffuse large B-cell lymphoma of the central nervous system.
    Nam SJ; Kim S; Kwon D; Kim H; Kim S; Lee E; Kim TM; Heo DS; Park SH; Lim MS; Kim CW; Jeon YK
    Oncoimmunology; 2018; 7(7):e1442164. PubMed ID: 29900049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
    Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
    Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of programmed cell death ligand-1 by immune cells in the microenvironment is a favorable prognostic factor for primary diffuse large B-cell lymphoma of the central nervous system.
    Tsuyuki Y; Ishikawa E; Kohno K; Shimada K; Ohka F; Suzuki Y; Mabuchi S; Satou A; Takahara T; Kato S; Miyagi S; Ozawa H; Kawano T; Takagi Y; Hiraga J; Wakabayashi T; Nakamura S
    Neuropathology; 2021 Apr; 41(2):99-108. PubMed ID: 33269495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diffuse large B-cell lymphoma: the significance of CD8
    Zhu Q; Yang Y; Chen K; Zhang Q; Huang Y; Jian S
    J Transl Med; 2024 Feb; 22(1):174. PubMed ID: 38369502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation.
    Rosado FG; Coberly J; Gupta A; John G; Naina H; Koduru P; Chen W
    Ann Clin Lab Sci; 2021 Mar; 51(2):174-181. PubMed ID: 33941556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.